Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer

Stefan Garczyk 1 · Felix Bischoff 1 · Ursula Schneider 1 · Reinhard Golz 2 · Friedrich-Carl von Rundstedt 3 · Ruth Knüchel 1 · Stephan Degener 3

Received: 13 November 2020 / Revised: 20 January 2021 / Accepted: 7 February 2021 / Published online: 1 March 2021 © The Author(s) 2021

Abstract
Reliable factors predicting the disease course of non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) are unavailable. Molecular subtypes have potential for prognostic stratification of muscle-invasive bladder cancer, while their value for CIS patients is unknown. Here, the prognostic impact of both clinico-pathological parameters, including CIS focality, and immunohistochemistry-based surrogate subtypes was analyzed in a cohort of high-risk NMIBC patients with CIS. In 128 high-risk NMIBC patients with CIS, luminal (KRT20, GATA3, ERBB2) and basal (KRT5/6, KRT14) surrogate markers as well as p53 were analyzed in 213–231 biopsies. To study inter-lesional heterogeneity of CIS, marker expression in independent CIS biopsies from different bladder localizations was analyzed. Clinico-pathological parameters and surrogate subtypes were correlated with recurrence-free (RFS), progression-free (PFS), cancer-specific (CSS), and overall survival (OS). Forty-six and 30% of CIS patients exhibited a luminal-like (KRT20-positive, KRT5/6-negative) and a null phenotype (KRT20-negative, KRT5/6-negative), respectively. A basal-like subtype (KRT20-negative, KRT5/6-positive) was not observed. A significant degree of inter-lesional CIS heterogeneity was noted, reflected by 23% of patients showing a mixed subtype. Neither CIS surrogate subtype nor CIS focality was associated with patient outcome. Patient age and smoking status were the only potentially independent prognostic factors predicting RFS, PFS, OS, and PFS, respectively. In conclusion, further clarification of heterogeneity of surrogate subtypes in HR NMIBC and their prognostic value is of importance with regard to potential implementation of molecular subtyping into clinical routine. The potential prognostic usefulness of patient age and smoking status for high-risk NMIBC patients with CIS needs further validation.

Keywords
NMIBC · Bladder cancer · CIS · Carcinoma in situ · Molecular subtypes · Intratumoral heterogeneity

Introduction
Bladder cancer (BC) is the most common malignancy of the urinary tract: an estimated number of 549,000 new cases and 200,000 deaths were registered in 2018 worldwide [1]. Muscle-invasive bladder cancer (MIBC) has an unfavorable prognosis (5-year survival <50%) and mainly develops from carcinoma in situ (CIS), a flat-growing, high-grade (HG) lesion characterized by frequent TP53 alterations [2].

Based on the current treatment guidelines by the European Association of Urology (EAU) and the American Urological Association (AUA) [3, 4], first-line intravesical bacillus Calmette-Guérin (BCG)-based immunotherapy following transurethral resection (TUR) of the tumor is recommended for treatment of high-risk (HR) non-MIBC (NMIBC), including patients exhibiting CIS lesions. However, BCG therapy fails in a substantial number of patients [5] caused by cessation of the therapy due to resistance or toxicity [6, 7]. Radical
cystectomy (RC) is recommended as second-line treatment in case of BCG failure [3, 4]. Although associated with an excellent tumor-specific survival [8], RC is a morbid surgery significantly impacting quality of life and thus not all patients are eligible or refuse RC [7]. Moreover, the RC-related rate of overtreatment is assumed to be high [5] due to a lack of reliable prognostic markers [3]. Obviously, there is a need for both, alternative bladder-preserving therapies and reliable prognostic markers allowing the identification of HR NMIBC patients with worse prognosis that might benefit from timely RC and those profiting most from conservative treatment.

Extensive molecular characterization of MIBC has led to the identification of different subtypes with divergent clinical outcomes. In general, a major luminal subgroup associated with favorable and a basal subtype exhibiting worse survival was discovered [9, 10]. Importantly, immunohistochemistry-based subgrouping by surrogate markers might allow feasible implementation of subtype stratification into clinical routine [11]. Regarding non-muscle-invasive urothelial cancer, preliminary data indicate that especially luminal-like urothelial lesions (of the upper tract and the urinary bladder) might be related with worse prognosis compared to those with basal phenotype [12, 13].

With regard to the lack of reliable prognostic stratification markers for HR NMIBC patients presenting with aggressive CIS lesions [3], we sought to analyze the potential prognostic impact of both clinico-pathological parameters including CIS focality and additionally immunohistochemistry-based surrogate subtypes of bladder cancer in a cohort of HR NMIBC patients with CIS. To the best of our knowledge, this is the first study analyzing the potential prognostic value of the recently described molecular subtypes, defined by immunohistochemical surrogate markers, in CIS lesions of HR NMIBC patients.

Materials and methods

Patient cohort

We retrospectively analyzed all patients \((n=2,792)\) undergoing transurethral bladder resection (TURBT) at the Urology Department of the Helios University Hospital Wuppertal between 2008 and 2014. In 1,424 of these patients (51%), a urothelial carcinoma was detected. Patients with concurrent or a history of prior MIBC were excluded \((n=285; 20\%)\). In total, 128 patients (11%) were diagnosed with CIS, with or without concurrent Ta and T1 high-risk NMIBC (Table 1). In all patients with Ta and T1 NMIBC, a re-TURBT was performed after 4–6 weeks. The NMIBC follow-up was performed according to the EAU NMIBC guideline [3]. A histological confirmation of a recurrence was mandatory during the follow-up. All clinico-pathological and follow-up data were obtained from the hospital records and two experienced uropathologists (RK and RG) reviewed the histological specimens of all patients to confirm the diagnosis. The median follow-up of the patient cohort was 66 months (range: 3–122 months). The study was conducted at the Helios University Hospital Wuppertal and the University Hospital RWTH Aachen in accordance with the requirements of the institutional review board of the University of Witten/Herdecke (No. 55/2019), the current version of the Declaration of Helsinki and the good clinical practice guidelines.

Our retrospective immunohistochemistry (IHC) cohort comprised altogether 266 biopsy samples from 128 patients (75 patients with multifocal, 53 cases with unifocal CIS). Due to differential availability of adequate CIS tissue material on prepared tissue microarrays (TMAs), variable numbers of biopsy samples (ranging from 213–231) were stained and analyzed for each IHC marker (Online Resource 1).

Immunohistochemistry

Formalin-fixed, paraffin-embedded (FFPE) CIS material was used to create tissue microarrays (TMAs). Positive and negative staining controls were included on all TMAs, CIS-heterogeneity, i.e., inter-lesional heterogeneity of multifocal CIS was considered by analyzing marker expression in independent biopsies taken from different CIS localizations in the same urinary bladder, respectively. In any case with sufficient available biopsy material, we additionally analyzed intra-lesional (intra-localization) heterogeneity by generating two to three TMA cores from the same biopsy. TMA sections (2 \(\mu\m) were incubated with antigen retrieval solution PT Link (Dako, Agilent, Santa Clara, California) of pH 6 (KRT14, KRT20, GATA3, ERBB2) and pH 9 (KRT5/6 and p53) at 95°C for deparaffinization, rehydration, and epitope retrieval. Slides were subsequently transferred to an automated immunostainer (Dako, Agilent) and covered with EnVision™ Flex Peroxidase Blocking-Reagent (Dako, Agilent) for 5 min. Next, immunostaining was performed using validated antibodies for KRT20, GATA3, ERBB2, KRT5/6, KRT14, and p53 [14, 15]. Subsequently, tissue sections were treated with a secondary reagent (Dako, Agilent) for 15 min, followed by incubation with a horseradish peroxidase-conjugated polymer (Dako, Agilent) for 20 min. Finally, visualization of staining was accomplished using a DAB+ Substrate Chromogen System (Dako, Agilent) and tissue sections were counterstained using Mayer’s hematoxylin.

All immunohistochemical stainings were assessed by an experienced uropathologist (RK). The percentage of positively stained cells was evaluated for the cytoplasmic markers KRT20, KRT5/6, KRT14, and nuclear p53. As described previously [14, 15], KRT20, KRT5/6, and KRT14 immunohistochemistry were evaluated with cutoffs of >50% as positive.
This value seems plausible to the experienced uropathologist, since it is sometimes hard to unequivocally exclude reactive changes of basal cells (KRT5/6 and KRT14 positive) and regenerative superficial cells (KRT20 positive), which may well be mixed in with the cells of carcinoma in situ. The fact that CIS can be pagetoid and does not have to include the whole thickness of the urothelium was taken into consideration, when semiquantitative evaluation was carried out. Aberrant p53 expression was assumed if either 100 % of cells exhibited intense nuclear staining or in case of complete absence of nuclear staining [16]. GATA3 expression was assessed using an adapted semi-quantitative immunoreactive scoring system [17], multiplying a score for nuclear staining intensity (from 0 to 3) with a score expressing the percentage of stained cells: 0%=0, <10%=1, 10-50%=2, 50-80%=3, >80%=4. A score ranging from 3-12 was considered “positive” as described recently [14]. The Dako score was used to

Table 1 Characteristics of HR NMIBC patients with CIS

| Characteristic                              | Number n=128 | %   |
|--------------------------------------------|--------------|-----|
| Age (median: 72 years, range: 44–89 years) |               |     |
| ≤ 72                                       | 65           | 51  |
| > 72                                       | 63           | 49  |
| Sex                                         |              |     |
| Male                                       | 107          | 84  |
| Female                                     | 21           | 16  |
| Smoking status                             |              |     |
| Never                                      | 70           | 55  |
| Former                                     | 31           | 24  |
| Current                                    | 27           | 21  |
| Prior UC<sup>a</sup>                        |              |     |
| Yes                                        | 37           | 29  |
| No, primary                                | 91           | 71  |
| Prior recurrence rate<sup>b</sup>           |              |     |
| Primary                                    | 91           | 71  |
| ≤ 1 recurrence/yr                          | 23           | 18  |
| > 1 recurrence/yr                          | 13           | 10  |
| unknown RR                                 | 1            | 1   |
| Prior intravesical therapy                 |              |     |
| BCG                                        | 12           | 9   |
| Mitomycin C                                | 1            | 1   |
| none                                       | 115          | 90  |
| BCG therapy<sup>c</sup>                    |              |     |
| No                                         | 38           | 30  |
| Yes                                        | 90           | 70  |
| CIS focality                               |              |     |
| Unifocal                                   | 53           | 41  |
| Multifocal                                 | 75           | 59  |
| CIS clinical type                          |              |     |
| Isolated CIS                               | 24           | 19  |
| Concurrent CIS                             | 104          | 81  |
| Concomitant pTa LG                         |              |     |
| Unifocal                                   | 11           | 9   |
| Multifocal                                 | 1            | 1   |
| None                                       | 116          | 91  |
| Concomitant pTa HG                         |              |     |
| Unifocal                                   | 36           | 28  |
| Multifocal                                 | 23           | 18  |
| None                                       | 69           | 54  |
| Concomitant pT1                            |              |     |
| Unifocal                                   | 45           | 35  |
| Multifocal                                 | 15           | 12  |
| None                                       | 68           | 53  |
| HG tumor focality                          |              |     |
| Unifocal                                   | 31           | 24  |
| Multifocal                                 | 97           | 76  |
| Recurrence at first follow-up              |              |     |
| No                                         | 112          | 88  |

Table 1 (continued)

| Characteristic                              | Number n=128 | %   |
|--------------------------------------------|--------------|-----|
| Yes                                        | 16           | 13  |
| Recurrence                                 |              |     |
| No                                         | 78           | 61  |
| Yes                                        | 50           | 39  |
| Progression                                |              |     |
| No                                         | 106          | 83  |
| Yes                                        | 22           | 17  |
| Survival                                   |              |     |
| Dead                                       | 55           | 43  |
| Alive                                      | 72           | 56  |
| Unknown                                    | 1            | 1   |
| Cause of death                             |              |     |
| UC                                         | 16           | 29  |
| Other                                      | 30           | 55  |
| Unknown cause of death                     | 9            | 16  |
| BCG response                               |              |     |
| Treatment success (including late relapse<sup>d</sup>) | 63 | 70 |
| BCG-unresponsive (including early relapse<sup>e</sup>) | 15 | 17 |
| BCG-failure                                | 10           | 11  |
| BCG-intolerant                             | 1            | 1   |
| Not specified                              | 1            | 1   |
| Radical cystectomy                         |              |     |
| No                                         | 90           | 70  |
| Yes                                        | 38           | 30  |

a: non-muscle-invasive bladder/upper tract urothelial carcinoma; b: low-grade recurrences are included; c: at least induction therapy; d: high-grade recurrence at ≥ 2 years after receipt of adequate BCG; e: high-grade recurrence at 6 months up to < 2 years. Percentages may not sum up to 100 % due to rounding. RR, recurrence rate; TURB, transurethral resection bladder; UC, urothelial carcinoma
quantify ERBB2 protein expression, combining staining intensity and the percentage of positive cells: 0-1 (negative), 2 (moderate), and 3 (positive, overexpressed) [18]. In case of analysis of several cores taken from the same biopsy material (intra-lesional heterogeneity), the mean staining results were calculated for cytokeratin and GATA3 expression, whereas the strongest staining result for ERBB2 was selected. P53 staining was considered aberrant if at least one of the cores showed aberrant staining.

**Statistical analysis**

Univariate Kaplan-Meier analysis and multivariate Cox proportional hazards regression models were used to identify potential prognostic factors for risk stratification of HR NMIBC patients with CIS. Clinically relevant covariates (based on relevant literature) and variables showing a statistically significant (logrank $p < 0.1$) association with the respective survival endpoint in univariate analysis were included in the multivariate models. A number of at least 10 events per included independent variable was considered in the multivariate models [19]. The level of significance in the multivariate analysis was set to $p < 0.05$. Recurrence-free survival was defined as the time interval from tumor resection at the time of study inclusion to first tumor recurrence, whereas progression-free survival was defined as the time interval from study inclusion to the first increase in stage. Overall and urothelial cancer-specific survival were defined as the time interval from study inclusion to death from any cause and death related to urothelial cancer, respectively. Patients without an event or death were censored at the last date of follow-up. All analyses were conducted by using IBM SPSS Statistics (version 26).

**Results**

**Patient characteristics**

The main characteristics of the HR NMIBC patients with CIS are summarized in detail in Table 1 and only a few data central to the topic may be pointed out. Twenty-nine percent of patients had a history of prior non-muscle-invasive urothelial carcinoma of the bladder and/or the upper tract. The majority of cases (90%) did not receive prior intravesical therapy and 70% of patients were treated with BCG (at least induction therapy) following the date of inclusion in the retrospective study. Forty-one percent of patients presented with unifocal CIS, whereas 59% exhibited multifocal CIS lesions. The majority of patients exhibited concurrent CIS lesions (81%) and a frequent association was found with papillary high-grade (pTa HG) tumors (46%) and only rarely with papillary low-grade (pTa LG) lesions (10%). By nature of a high-grade lesion, CIS in an identical bladder location as a high-grade papillary tumor cannot be differed from a flat rim of a papillary tumor. Stromainvasive disease (pT1) was found in 47% of all patients. Isolated CIS lesions were identified in 19% of all patients and of those 29% were primary CIS. BCG treatment success, defined as a disease-free state for at least 2 years after receipt of adequate BCG therapy, was observed in 70% of BCG-treated cases (63/90). Further, 17%, 11% and 1% were categorized as BCG-unresponsive, BCG-failure and BCG-intolerant cases, respectively [7].

**Prognostic impact of clinico-pathologic parameters**

The median follow-up for the patient cohort was 66 months (range: 3–122 months). Within this time frame, a portion of 39% (50/128 patients) experienced at least one recurrence, with a median time to first recurrence of 15 months. Seventeen percent of patients (22/128) showed progressive disease, with a median time to progression of 19 months. Forty-three percent of patients (55/128) died within the follow-up period and 29% of deaths were related to urothelial cancer.

In the univariate analysis, the following clinico-pathological parameters were identified to be of potential relevance to predict disease recurrence (patient age), disease progression (smoking status, patient age), urothelial cancer-specific survival (patient age, CIS clinical type, concomitant pT1, BCG therapy) and overall survival (patient age, BCG therapy, recurrence at first follow-up) (Table 2). Due to limited group sizes, the parameter “concomitant pTa LG” was excluded from the univariate analysis.

**Prognostic impact of molecular CIS subtypes**

To date, it is unclear if molecular subtypes might have a relevance for prognostic stratification of HR NMIBC as shown for MIBC [10, 20]. Here, we analyzed subtype IHC-surrogate marker expression [11] in the CIS lesion(s) of each HR NMIBC patient with available tissue material, comprising luminal (KRT20, GATA3, ERBB2) and basal (KRT5/6, KRT14) markers as well as p53 as a diagnostic marker. Inter-lesional CIS heterogeneity was considered by analyzing marker expression in independent biopsies taken from different CIS localizations in the same urinary bladder, respectively. In agreement with our previous findings in an independent cohort of isolated CIS cases [14], positivity for luminal markers was observed in the majority of CIS biopsies while predominantly lacking expression of basal cytokeratins (Online Resource 1).

Recently, the potential utility of a two-marker-based approach has been suggested as a prognostic stratification system for MIBC and NMIBC patients [11, 13]. Applying KRT20 and KRT5/6 protein expression as luminal and basal surrogate marker respectively, HR NMIBC patients with CIS
Table 2: Univariate analysis of clinico-pathologic parameters and surrogate molecular CIS subtype

| Variable                        | RFS  |       | PFS  |       | CSS  |       | OS   |       |
|---------------------------------|------|-------|------|-------|------|-------|------|-------|
|                                 | n/event | p<0.1 | n/event | p<0.1 | n/event | p<0.1 | n/event | p<0.1 |
| Age (years)                     | <0.001 | 0.052 | 0.021 | <0.001 | 0.333 | 0.290 | 0.170 | 0.564 |
| ≤ 72                            | 65/17 | 65/8  | 63/5 | 64/10 |       |       |      |       |
| > 72                            | 63/33 | 63/14 | 55/11 | 63/45 |       |       |      |       |
| Sex                             | 0.695 | 0.895 | 0.978 | 0.205 | 0.183 | 0.488 | 0.048 | 0.174 |
| Male                            | 107/42 | 107/18 | 97/13 | 106/48 |       |       |      |       |
| Female                          | 21/8  | 21/4  | 21/3 | 21/7  |       |       |      |       |
| Smoking                         | 0.016 | 0.006 | 0.524 | 0.290 |       |       |      |       |
| Never                           | 70/24 | 70/10 | 65/7 | 70/28 |       |       |      |       |
| Former                          | 31/12 | 31/2  | 30/5 | 31/16 |       |       |      |       |
| Current                         | 27/14 | 27/10 | 23/4 | 26/11 |       |       |      |       |
| Prior UC                        | 0.607 | 0.184 | 0.782 | 0.170 |       |       |      |       |
| No                              | 91/37 | 91/13 | 85/11 | 90/34 |       |       |      |       |
| Yes                             | 37/13 | 37/9  | 33/5 | 37/21 |       |       |      |       |
| Prior RR                        | 0.724 | 0.126 | 0.503 | 0.183 |       |       |      |       |
| Primary                         | 91/37 | 91/13 | 85/11 | 90/34 |       |       |      |       |
| ≤ 1                             | 23/9  | 23/7  | 20/4 | 23/14 |       |       |      |       |
| > 1                             | 13/4  | 13/2  | 12/1 | 13/7  |       |       |      |       |
| Prior intravesical therapy      | 0.527 | 0.147 | 0.694 | 0.564 |       |       |      |       |
| No                              | 115/44 | 115/18 | 106/15 | 114/48 |       |       |      |       |
| Yes                             | 13/6  | 13/4  | 12/1 | 13/7  |       |       |      |       |
| BCG therapy                     | 0.301 | 0.933 | 0.077 | 0.048 |       |       |      |       |
| No                              | 38/11 | 38/6  | 33/7 | 38/22 |       |       |      |       |
| Yes                             | 90/39 | 90/16 | 85/9 | 89/33 |       |       |      |       |
| Recurrence at first FU          | 0.623 | 0.263 | 0.022 |       |       |       |      |       |
| No                              | -    | 112/19 | 104/13 | 111/44 |       |       |      |       |
| Yes                             | -    | 16/3  | 14/3 | 16/11 |       |       |      |       |
| CIS focality                    | 0.463 | 0.301 | 0.302 | 0.659 |       |       |      |       |
| Unifocal                        | 53/18 | 53/7  | 51/5 | 53/22 |       |       |      |       |
| Multifocal                      | 75/32 | 75/15 | 67/11 | 74/33 |       |       |      |       |
| HG tumor focality               | 0.476 | 0.927 | 0.402 | 0.245 |       |       |      |       |
| Unifocal                        | 31/14 | 31/6  | 30/3 | 31/11 |       |       |      |       |
| Multifocal                      | 97/36 | 97/16 | 88/13 | 96/44 |       |       |      |       |
| CIS clinical type               | 0.914 | 0.742 | 0.038 | 0.174 |       |       |      |       |
| Isolated                        | 24/10 | 24/4  | 22/0 | 24/8  |       |       |      |       |
| Concurrent                      | 104/40 | 104/18 | 96/16 | 103/47 |       |       |      |       |
| Concomitant pTa HG              | 0.792 | 0.970 | 0.859 | 0.825 |       |       |      |       |
| No                              | 69/28 | 69/12 | 63/9 | 68/31 |       |       |      |       |
| Yes                             | 59/22 | 59/10 | 53/7 | 59/24 |       |       |      |       |
| Concomitant pT1                 | 0.907 | 0.521 | 0.044 | 0.291 |       |       |      |       |
| No                              | 68/28 | 68/11 | 63/5 | 68/27 |       |       |      |       |
| Yes                             | 60/22 | 60/11 | 55/11 | 59/28 |       |       |      |       |
| Molecular CIS subtype           | 0.768 | 0.779 | 0.996 | 0.846 |       |       |      |       |
| Null                            | 30/11 | 30/6  | 28/4 | 30/12 |       |       |      |       |
| Mixed                           | 23/8  | 23/3  | 21/3 | 22/8  |       |       |      |       |
| Luminal                         | 46/20 | 46/9  | 43/6 | 46/22 |       |       |      |       |
| Molecular CIS subtype           | 0.488 | 0.700 | 0.962 | 0.564 |       |       |      |       |
| Non-luminal                     | 53/19 | 53/9  | 49/7 | 52/20 |       |       |      |       |
| Luminal                         | 46/20 | 46/9  | 43/6 | 46/22 |       |       |      |       |

*p values < 0.1 were considered significant and are shown in italics
a: logrank test, b: cases defined to exhibit a “null” and “mixed” subtype respectively; CSS, urothelial cancer-specific survival; FU, follow-up, OS, overall survival; PFS, progression-free survival; RFS, recurrence-free survival; RR, recurrence rate; UC, urothelial carcinoma
were stratified into the three major CIS groups “luminal”, “null” and “mixed,” while the latter comprised four subgroups due to heterogenous inter-lesional marker expression in different CIS localizations of the same patients (Table 3, Fig. 1 and Online Resource 2). Due to unavailability of CIS tissue material on the respective TMAs for KRT20 and KRT5/6 staining, stratification was valid for 99 of 128 patients. Importantly, a “basal-like” subtype (KRT20 negative, KRT5/6 positive) was not observed. The majority (46 %, 46/99 cases) of CIS patients was characterized as “luminal”, whereas 30% (30/99 cases) and 23% (23/99 cases) exhibited a “null” and “mixed” phenotype, respectively. No statistically significant association between surrogate molecular CIS subtype of HR NMIBC patients and survival was noted (Table 2).

**Multivariate analysis**

Depending on the number of events for RFS, PFS, CSS, and OS in the current study, observed significance of factors in the univariate analysis ($p < 0.1$) and recently described prognostic potential of factors for stratification of BCG-treated NMIBC patients associated with CIS [21, 22], the following variables were subsequently included in the multivariate models: RFS (age, sex, prior UC, CIS focality), PFS (smoking status, age), and OS (age, BCG therapy, recurrence at first follow-up, concomitant pT1) (Table 4). Due to a limited number of events, multivariate analysis for CSS was not valid and thus not performed.

In the multivariate models, patient age was significantly associated with RFS, PFS, and OS, whereas smoking status was identified as a potential independent predictor of PFS in HR NMIBC patients with CIS.

**Table 3**  
CIS patient stratification into three major groups based on KRT20 and KRT5/6 protein expression

| Major CIS group | CIS subgroup | Marker expression | Patients |
|-----------------|--------------|-------------------|---------|
| -               | -            | -                 | 99 (100 %) |
| luminal         | -            | KRT20 positive    | 46 (46 %) |
|                 |              | KRT5/6 negative   |         |
| null            | -            | KRT20 negative    | 30 (30 %) |
|                 |              | KRT5/6 negative   |         |
| mixed           | -            | -                 | 23 (23 %) |
| 1               | KRT20 mixed  | 18                |         |
|                 | KRT5/6 positive |         |         |
| 2               | KRT20 mixed  | 3                 |         |
|                 | KRT5/6 mixed |         |         |
| 3               | KRT20 negative| 1                |         |
|                 | KRT5/6 mixed |         |         |
| 4               | KRT20 mixed  | 1                 |         |
|                 | KRT5/6 positive |        |         |

**Discussion**

Currently, no reliable prognostic factors are available to predict the disease course of CIS patients [3]. Thus, there is an unmet need to identify markers allowing stratification of CIS patients into those cases benefiting most from early radical cystectomy and those profiting from conservative treatment.

Existing prognostic scores and risk tables are based on data from studies that were not specifically focused on CIS patients [21, 23, 24]. The European Organisation for Research and Treatment of Cancer (EORTC) scoring system for instance was developed on the basis of survival data from NMIBC patients mostly without CIS, and predominantly treated by chemotherapy [23]. The basis of the CUETO (Club Urologico Espanol de Tratamiento) model are data from NMIBC patients treated by suboptimal BCG therapy and again, patients with CIS only represented a small fraction (10% of patients) [21]. In a more recent study, potential prognostic factors in intermediate and high-risk NMIBC patients treated with 1–3 years maintenance BCG were investigated, however, without inclusion of CIS patients [24]. Indeed, several smaller studies analyzing the prognostic value of different factors specifically in CIS patients, including established clinico-pathological parameters, have been performed. For instance, exhibiting concurrent CIS and T1 lesions compared to primary CIS [25], having an extended CIS [26] and CIS localized in the prostatic urethra [27] have been associated with worse patient outcome. It may be emphasized here that all studies are limited to mere histological diagnosis of CIS as a variable, without any further analysis of the lesional biology.

Molecular subtypes have been described previously in MIBC, resembling those found in breast cancer patients [10, 20]. Importantly, these subtypes seem promising with regard to prognostic stratification of MIBC patients, with basal tumors being potentially associated with a more aggressive behavior in comparison to luminal cancers while putatively responding better to chemotherapy than luminal carcinomas [10, 20].

Far less is known about the impact of these molecular subtypes in NMIBC patients. In contrast to MIBC, first data in NMIBC and non-muscle-invasive urothelial cancer of the upper urinary tract indicate that especially luminal-like tumors are associated with an unfavorable outcome [12, 13, 28–30]. The use of a minimal set of immunohistochemical markers (including KRT20 and KRT5/6) has been demonstrated to be a feasible and reliable approach to reflect intrinsic molecular subtypes (at least) in MIBC samples [11].

In a previous study without clinical follow-up, we have shown that isolated CIS lesions are characterized by the expression of luminal markers including KRT20 and GATA3, whereas lacking the expression of the basal cytokeratins KRT5/6 and KRT14 in the majority of samples [14]. In the current study, we were able to validate our previous
observations in a large, independent cohort of HR NMIBC patients with CIS. In addition to our previous analyses, we considered the inter-lesional CIS-heterogeneity of marker expression in CIS patients by analyzing marker expression in different CIS localizations in the same urinary bladders and observed a significant degree of heterogeneity. Using

Fig. 1 Surrogate CIS subtypes. Based on KRT20 and KRT5/6 expression, high-risk NMIBC patients with CIS were stratified into surrogate subtypes. Exemplary luminal case, characterized by consistent positivity for KRT20 as well as absence of KRT5/6 in the tumor cells in three distinct CIS localizations in the same urinary bladder (a and b). Exemplary high-risk NMIBC patient with CIS showing a mixed KRT20 phenotype, i.e., KRT20 tumor cell positivity in only two of three distinct CIS localizations in the same urinary bladder but consistent KRT5/6 CIS cell negativity (c and d). Boxed areas in each micrograph are shown in higher magnification. Scale bars: 100μm
KRT20 and KRT5/6 as luminal and basal surrogate marker respectively, CIS patients were categorized into the three major groups “luminal,” “null,” and “mixed,” while the latter comprised different subgroups due to heterogenous KRT20 and KRT5/6 expression in different CIS localizations. Of note, we did not observe a clear “basal” phenotype in our CIS cohort (KRT20 negative, KRT5/6 positive). In contrast to two recent studies in NMIBC [13, 29], we did not observe a significant association of surrogate CIS subtype with patient outcome. This observation remained stable when using additional cutoffs for KRT20 and KRT5/6 positivity (30% and 80% respectively) (data not shown). These putatively conflicting observations might be explained by significant differences between these studies: First, using RNA data, Breyer et al. focused on surrogate subtypes solely in T1 tumors of NMIBC patients [13]. The second study included stage Ta and T1 NMIBC patients, with a substantial fraction of LG tumors (65%), analyzing surrogate subtypes in Ta and T1 samples [29]. Second, neither of the aforementioned studies considered potential intratumoral heterogeneity (ITH) in Ta and T1 tumors investigated, even though known to be relevant in bladder tumors including heterogeneity with regard to molecular subtypes [31, 32]. While intratumoral heterogeneity in bladder cancer of different stages and grade, except for CIS, has been studied before [33] it has remained unclear thus far if surrogate subtypes differ when considering distinct tumor localizations present in the same urinary bladder and neither is validated which tumor locus is prognostically informative with regard to molecular subtypes in case of heterogeneity. Data from our previous work suggest that there might be considerable ITH in surrogate molecular subtypes, as a switch from a luminal-like to a more basal-like phenotype was observed during the course of stroma-invasion of CIS lesions [14]. We hypothesize that the surrogate molecular subtype of the highest stage and grade lesion in NMIBC

| Variable                        | RFS |          | PFS |          | OS |          |
|---------------------------------|-----|----------|-----|----------|----|----------|
|                                 | HR (95% CI) | p    | HR (95% CI) | p    | HR (95% CI) | p    |
| Age ≤ 72                        | 1.00 | -      | 1.00 | -      | 1.00 | -        |
| Age > 72                        | 3.23 (1.73–6.04) | <0.001 | 3.08 (1.26–7.54) | 0.014 | 7.38 (3.63–15.01) | <0.001 |
| Sex Female                      | 1.00 | -      | -   | -      | -   | -        |
| Sex Male                        | 0.78 (0.35–1.77) | 0.557 | -   | -      | -   | -        |
| Prior UC Yes                    | 1.00 | -      | -   | -      | -   | -        |
| Prior UC No                     | 1.62 (0.82–3.21) | 0.166 | -   | -      | -   | -        |
| Concomitant pT1 No              | -   | -      | -   | -      | -   | -        |
| Concomitant pT1 Yes             | -   | -      | -   | -      | -   | 1.00     |
| CIS focality Unifocal           | 1.00 | -      | -   | -      | -   | -        |
| CIS focality Multifocal         | 1.12 (0.62–2.01) | 0.704 | -   | -      | -   | -        |
| Smoking status Never            | -   | -      | -   | -      | -   | -        |
| Smoking status Former           | -   | -      | -   | -      | -   | 1.00     |
| Smoking status Current          | 0.54 (0.12–2.45) | 0.420 | -   | -      | -   | -        |
| BCG therapy No                  | -   | -      | -   | -      | -   | -        |
| BCG therapy Yes                 | -   | -      | -   | -      | -   | 1.00     |
| Recurrence at first FU No       | -   | -      | -   | -      | -   | -        |
| Recurrence at first FU Yes      | -   | -      | -   | -      | -   | 0.62 (0.35–1.09) | 0.099 |

p values < 0.05 were considered significant and are shown in italics
CI, confidence interval; FU, follow-up, HR, hazard ratio, OS, overall survival, PFS, progression-free survival, RFS, recurrence-free survival; UC, urothelial carcinoma
might be prognostically informative and this hypothesis will be analyzed in upcoming studies.

Bladder cancer frequently presents as a multifocal disease, potentially representing different tumor clones of a monoclonal origin [31, 34]. In the current study cohort, 59% and 76% of patients had multifocal CIS lesions and multifocal HG tumors (including papillary HG and pT1 lesions), respectively. It was hypothesized that CIS/HG multifocality is related to worse outcome compared to patients with unifocal CIS/HG tumors. This hypothesis is based on the assumption that a more diverse tumor is able to adapt more efficiently to changing environmental conditions resulting in faster tumor (re-)growth and progression [35]. To our knowledge, the potential prognostic significance of CIS/HG focality in CIS patients is unclear and understudied to date. Surprisingly, neither CIS focality nor HG tumor focality in general were significantly associated with survival in the present cohort. This observation is in accordance with a smaller previous study noting that the extent of CIS is not predictive of recurrence or progression [36]. In contrast, Takenaka and colleagues observed a worse PFS in CIS patients with extended CIS [26].

Additionally, we analyzed the prognostic potential of a larger set of established clinico-pathological factors. Higher patient age was identified as a potential independent prognostic parameter of an unfavorable recurrence-free (RFS), progression-free (PFS) and overall survival (OS) of HR NMIBC patients with CIS. Due to a limited number of events, multivariate analysis for urothelial cancer-specific survival has not been performed. However, a significant association of higher age with worse urothelial cancer-specific survival has been noted in univariate analysis as well. An association of increasing age with worse RFS, PFS, OS, and bladder cancer-specific survival has been observed previously in studies considering NMIBC including patients with CIS [21, 22]. Concerning studies specifically focusing on CIS patients, conflicting observations have been made [26, 37]. Moreover, we noted that current smokers exhibited a significantly worse PFS compared to never smokers and former smokers. Interestingly, no significant difference in PFS was observed between never and former smokers. The value of smoking status as a prognostic stratification marker in non-muscle-invasive bladder cancer is controversial [38, 39]. Focusing specifically on patients with CIS, smoking status has to our knowledge so far not been identified as an independent prognostic factor for PFS and needs further validation [37, 40].

The current study is limited by its retrospective character. Even though the study includes a high number of cases with CIS related to its overall frequency in the bladder, we are aware of case numbers being still fairly small for the observations stated. Even though an obvious degree of inter-lesional CIS heterogeneity with regard to surrogate molecular subtypes was identified in this study, we are aware that the use of tissue microarrays instead of whole tissue slides is a limitation.

In summary, we observed that only patient age and smoking status information were independently associated with outcome of HR NMIBC with CIS. Neither the surrogate molecular subtype of CIS lesions in HR NMIBC patients, nor CIS/HG tumor focality were significantly related to prognosis. Importantly, we identified a considerable degree of inter-lesional CIS heterogeneity with regard to surrogate molecular subtypes and conclude that further clarification of potential heterogeneity in HR NMIBC patients is of high value with regard to potential implementation of molecular subtyping into clinical routine. Moreover, due to the putative transient/heterogenous nature of expression-based molecular subtypes in NMIBC, the prognostic impact of mutational profiles should be considered in upcoming studies.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00428-021-03054-0.

Acknowledgements We thank the Uropathology laboratory core team and the working group of Prof. Gaisa for excellent assistance.

Author contribution Conceptualization (SG, RK, SD); methodology (US, FB); investigation (FB, RK, SD, SG); formal analysis (SG, SD, FB); writing—original draft preparation (SG); writing—review and editing (RK, SD, FB, US, FCR, RG); Resources (FCR, RG); supervision (RK, SG, SD). All authors read and approved the final version of the manuscript.

Funding Open Access funding enabled and organized by Projekt DEAL.

Data availability All data underlying the reported findings are included within the manuscript and its supplements. Raw datasets generated during the current study are available from the corresponding author on reasonable request.

Code availability Not applicable

Declarations

Ethics approval The retrospective, anonymous study on archived human tissue material was conducted at the Helios University Hospital Wuppertal and the University Hospital RWTH Aachen in accordance with the requirements of the institutional review board of the University of Witten/Herdecke (No. 55/2019), the current version of the Declaration of Helsinki, and the good clinical practice guidelines.

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain...
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492

2. Knowles MA, Hurst CD (2015) Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 15:25–41. https://doi.org/10.1038/nrc3817

3. Babjiu M, Burger M, Comperat EM, Gontero P, Mostafid AH, Palou J, van Rhijn BWG, Roupnet M, Sharifat SF, Zigerer R, Ziegener R, Capoun O, Cohen D, Escrig JLD, Hernández V, Peyronnet B, Seisen T, Soukop V (2019) European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol 76:639–657. https://doi.org/10.1016/j.eururo.2018.09.016

4. Taylor J, Becher E, Steinberg GD (2020) Update on the guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int 125:197–205. https://doi.org/10.1111/bju.14915

5. Sylvester RJ, van der Meijden A, Witjes JA, Jakse G, Nonomura N, Cheng C, Torres A, Watson R, Kurth KH (2005) High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 66:90–107. https://doi.org/10.1016/j.urology.2005.06.135

6. Tang DH, Chang SS (2015) Management of carcinoma in situ of the bladder: best practice and recent developments. Ther Adv Urol 7:351–364. https://doi.org/10.1177/1756287215599694

7. Nykopp TK, Batista da Costa J, Mannas M, Black PC (2018) Current Clinical Trials in Non-muscle Invasive Bladder Cancer. Curr Urol Rep 19:101. https://doi.org/10.1007/s11934-018-0852-6

8. Herr HW, Sogani PC (2001) Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 166:1296–1299

9. Robertson AG, Kim J, Al-Ahmadi H, Bellmunt J, Guo G, Cherniak AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Cherniak BA, Reuter VE, Xu X, de Sa Carvalho B, Chagas VS, Mungall AJ, Meyerson M, McConkey DJ, Moinzadeh P, Lane BR, Leraas KM, Lerner SP, Lichtenberg TM, Liu J, Parker PJ, Perry L, Pihl T, Porten S, Quintero-Aguilo ME, Ramirez NC, Rathmell WK, Reuter VE, Rieber-Christ K, Robertson AG, Sadeghi S, Saller C, Salner A, Sanchez-Vega F, Sandusky G, Scalapentino-C, Schein JE, Schuckman AK, Schultz N, Shelton C, Sholton T, Shukla SA, Simko J, Singh P, Sipahimalani P, Smith ND, Sofia JH, Sorcini A, Stanton ML, Steinberg GD, Stoehr R, Su X, Sullivan T, Sun Q, Tam A, Tamuzzer R, Tarvin K, Taubert H, Tiessen N, Thorne L, Tse K, Tucker K, Van Den Berg DJ, van Kessel KE, Wach S, Wan Y, Wang Z, Weinstein JN, Weisenberger DJ, Wise L, Wong T, Wu Y, Wu CJ, Yang L, Zach LA, Zenklusen JC, Zhang J, Zhang J, Zhuoda E, Zwartveld EC (2017) Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell 171:540–556.e25. https://doi.org/10.1016/j.cell.2017.09.007

10. Choi W, Porten S, Kim S, Willis D, Pliamark ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee I-L, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Cherniak B, Dinney CPN, McConkey DJ (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152–165. https://doi.org/10.1016/j.ccr.2014.01.009

11. Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Cherniak B (2016) Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. EBioMedicine 12:105–117. https://doi.org/10.1016/j.ebiom.2016.08.036

12. Jung M, Kim B, Moon KC (2019) Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma. Histopathology 74:483–493. https://doi.org/10.1111/his.13763

13. Breyer J, Wirtz RM, Otto W, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Eitz D, Denzinger S, Burger M, Hartmann A, on behalf of the BRIDGE Consortium (2017) In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRRT2 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.Virchows Arch 470:267–274. https://doi.org/10.1007/s00428-017-2064-8

14. Barth I, Schneider U, Grimm T, Karl A, Horst D, Gaia NT, Knüchel R, Garzsky S (2018) Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications. Virchows Arch 472:749–758. https://doi.org/10.1007/s00428-018-2354-9

15. Schnitzler T, Ortiz-Büchle N, Schneider U, Lurje I, Guricova K, Buchner A, Schulz GB, Heidenreich A, Gaia NT, Knüchel R, Garzsky S (2020) Pure high-grade papillary urinary bladder cancer: a luminal-like subgroup with potential for targeted therapy. Cell Oncol (Dordr) 43:807–819. https://doi.org/10.1007/s00044-020-00524-6

16. Hodgson A, Xu B, Downes MR (2017) p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant. Histopathology 71:296–304. https://doi.org/10.1111/his.13225

17. Remmel W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Patholology 8:138–140

18. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ (2000) Assessment of Methods for Tissue-Based Detection of the HER-2/neu Alteration in Human Breast Cancer: A Direct Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry. J Clin Oncol 18:3651–3664. https://doi.org/10.1200/JCO.2000.18.21.3651

19. Peduzzi P, Conrado J, Feinseth AR, Holford TR (1995) Importance of events per independent variable in proportional hazards
regression analysis II. Accuracy and precision of regression estimates. J Clin Epidemiol 48:1503–1510. https://doi.org/10.1016/0895-4356(95)00048-8

20. Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wokber SE, Yeh JJ, Milowsky MI, Iyer G, Parker JS, Kim WY (2014) Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 111: 3110–3115. https://doi.org/10.1073/pnas.1318376111

21. Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L, González M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Rababán M, Astobieta A, Montesinos M, Isorna S, Muntañola P, Gimeno A, Blas M, Martinez-Piñeiro JA (2009) Predicting non-muscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 182:2195–2203. https://doi.org/10.1016/j.juro.2009.07.016

22. Gontero P, Sylvester R, Pisano F, Joniau S, Vandekerckhove J, Fristrup N, Borre M, Hartmann A, Birkenkamp-Demtröder K, Ørntoft TF, Dyrskjøt L (2016) Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell 30:327–337. https://doi.org/10.1016/j.ccell.2016.05.004

23. Griffiths TRL, Charlton M, Neal DE, Powell PH (2002) Treatment of bladder cancer. Lancet 360:2412–2417. https://doi.org/10.1016/S0140-6736(02)10879-5

24. Palou J, Sylvester RJ, Faba O, Kurth K, Bouffioux C, Denis L, Newling DWW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC Trials. Eur Urol 49:466–477. https://doi.org/10.1016/j.eururo.2005.12.031

25. Griffths TRL, Charlton M, Neal DE, Powell PH (2002) Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol 167:2408–2412. https://doi.org/10.1016/S0022-5347(02)01764-3

26. Takenaka A, Yamada Y, Miyake H, Hara I, Fujisawa M (2008) Combined Analysis of Primary Carcinoma in Situ of the Bladder after Bacillus Calmette-Guerin: A Retrospective Study. Urol Int 101:269–276. https://doi.org/10.1159/000492121

27. Chun FK, Scherr DS, Shariat SF (2013) Impact of smoking and timing of smoking cessation on clinical outcomes in non-muscle-invasive bladder cancer. Urol Oncol 33:65.e12. https://doi.org/10.1016/j.urolonc.2014.06.002

28. Hedegaard L, Lamy P, Nordentoft I, Lamy P, Vang S, Reintert T, Herbertsson M, Johansson R, Frea B, Soukup V, Xylinas E, Dalbagni G, Karnes RJ, Fristrup N, Borre M, Hartmann A, Birkenkamp-Demtröder K, Dyrskjøt L, Ørntoft TF, Dyrskjøt L (2016) Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell 30:27–42. https://doi.org/10.1016/j.ccell.2016.05.004

29. Rej JR, Aguilar P, Blanca A, Moonen CM, Cammarata P, Cheng L, Henriques V, Lobato-Faria P, Lopez-Beltran A (2019) Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype. Virchows Arch 475:445–455. https://doi.org/10.1007/s00428-019-02593-x

30. Säde J, Keck B, Wach S, Taubert H, Wullich B, Goebell PJ, Kuhlmann A, Olbert P, Isfort P, Nimphius W, Hartmann A, Giedl J (2017) Immuno-histochemical subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis. PLoS One 12:e0179602. https://doi.org/10.1371/journal.pone.0179602

31. Thomsen MBH, Nordentoft I, Lamy P, Vang S, Reinert L, Mapendano CK, Hayer S, Ormtof TF, Jensen JB, Drjakoj L (2017) Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer. Sci Rep 7:11702. https://doi.org/10.1038/s41598-017-11291-0

32. Warrick SJ, Sjödahl K, Magan M, Raman JD, Merril S, Shuman L, Chen G, Walter V, DeGriff DJ (2019) Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants. Eur Urol 75:18–22. https://doi.org/10.1016/j.eururo.2018.09.003

33. Jakobsson L, Chebil G, Marzouka NAD, Liedberg F, Sjödahl G (2018) Low Frequency of Intratumor Heterogeneity in Bladder Cancer Tissue Microarrays. Bladder Cancer 4:327–337. https://doi.org/10.3233/BLC-180176

34. Habuchi T (2005) Origin of multifocal carcinomas of the bladder and upper urinary tract: Molecular analysis and clinical implications. Int J Urol 12:709–716. https://doi.org/10.1111/j.1442-2042.2005.01155.x

35. Gay L, Baker A-M, Graham TA (2016) Tumour Cell Heterogeneity, f1000research 5:238. https://doi.org/10.21203/f1000research.7210.1

36. van Gils-Gielen RJM, Debruyne FMJ, Witjes WPJ, Witjes JA, Caris CTM, Oosterhof GON (1995) Risk factors in carcinoma in situ of the urinary bladder. Urology 45:581–586. https://doi.org/10.1016/S0090-4295(99)80047-8

37. Kim SJ, Nam W, You D, Jeong IG, Song C, Hong B, Kim CS, Ahn H, Hong JH (2018) Prognostic Factors Related to Recurrence-Free Survival for Primary Carcinoma in situ of the Bladder after Bacillus Calmette-Guérin: A Retrospective Study. Urol Int 101:269–276. https://doi.org/10.1159/000492121

38. Rink M, Furbeg H, Zabor EC, Xylinas E, Babjuk M, Pycha A, Lotan Y, Karakiewicz PI, Novara G, Robinson BD, Montorsi F, Chun FK, Scherr DS, Sjärf SJ (2013) Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. Eur Urol 63:724–732. https://doi.org/10.1016/j.eururo.2012.08.025

39. Grotenhuis AJ, Ebben CW, Abbé KN, Witjes JA, Vrielink A, Vermeulen SH, Kiemeney LA (2015) The effect of smoking and timing of smoking cessation on clinical outcomes in non-muscle-invasive bladder cancer. Urol Oncol In Press 33:65.e9–65.e17. https://doi.org/10.1016/j.urolonc.2014.06.002

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.